Marilyn J Tan, MD
Endocrinology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 19
- 4 carriers
- Offices
- 2
- Since medical school
- 17 years
- Boston University School of Medicine, 2009
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
19 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
19 of 19 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A113366 · Current
Licensed to practise in California · since 2010 · expires 2027-10-31 · Boston University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$184,641
Medicare paid this office $184,641 for 429 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 165 | $56,645 | $71 |
| Return visit (30+ min) | 178 | $43,675 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $24,616 | $106 |
| Long return visit (40+ min) | 73 | $19,363 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $16,585 | $155 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 165 | $56,645 | $71 |
| Return visit (30+ min) | 178 | $43,675 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $24,616 | $106 |
| Long return visit (40+ min) | 73 | $19,363 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $16,585 | $155 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 71 | $6,379 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 49 | $5,835 | $117 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 140 | $3,489 | $15 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $2,053 | $121 |
| Return visit (30+ min) | 14 | $1,056 | $70 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 58 | $814 | $13 |
Who their Medicare patients are
429 Original Medicare patients in 2024. Average age 71 · Under 65 14% · 85 and older 8% · Women 50% · Also on Medicaid 34% · Health risk score 2.79. Sicker patients than 9 in 10 peers; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 50% · Coronary heart disease 42% · Heart failure 31% · Atrial fibrillation 28% · Depression 27% · Cancer 24% · COPD 21% · Dementia 16% · Stroke 14%.
The office billed $927,043, Medicare allowed $236,926 and paid $184,641; for 2,277 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 429 | 2,277 | 71 | 2.79 | $927,043 | $184,641 |
| 2023 | 368 | 1,645 | 70 | 3.02 | $713,627 | $135,003 |
| 2022 | 316 | 1,387 | 69 | 2.48 | $572,015 | $105,954 |
| 2021 | 349 | 1,563 | 70 | 2.42 | $673,953 | $125,117 |
| 2020 | 344 | 1,216 | 69 | 2.58 | $468,724 | $90,806 |
| 2019 | 361 | 1,316 | 69 | 2.27 | $336,832 | $104,762 |
| 2018 | 337 | 1,340 | 69 | 2.55 | $338,417 | $109,013 |
| 2017 | 283 | 1,129 | 68 | 2.34 | $303,233 | $92,418 |
| 2016 | 243 | 863 | 69 | 2.20 | $246,241 | $71,564 |
| 2015 | 223 | 865 | 68 | 2.41 | $229,545 | $65,480 |
| 2014 | 111 | 296 | 67 | 1.97 | $66,236 | $19,323 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 135 | $46,694 | $73 |
| Return visit (30+ min) | 131 | $21,200 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $18,978 | $110 |
| Long return visit (40+ min) | 74 | $14,246 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $13,634 | $160 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 61 | $4,797 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $4,185 | $120 |
| Return visit (30+ min) | 36 | $3,371 | $82 |
| Long return visit (40+ min) | 16 | $2,068 | $129 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,982 | $83 |
| Telehealth originating site facility fee | 50 | $868 | $17 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 23 | $619 | $23 |
2022: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $28,833 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $13,109 | $94 |
| Long return visit (40+ min) | 62 | $10,666 | $125 |
| Return visit (30+ min) | 89 | $10,201 | $78 |
| Long return visit (40+ min) | 50 | $9,820 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,739 | $180 |
| Return visit (30+ min) | 67 | $9,183 | $97 |
| Telehealth originating site facility fee | 100 | $2,996 | $19 |
| Extended patient service without direct patient contact, first hour | 31 | $2,863 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,709 | $123 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 45 | $2,368 | $30 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 37 | $1,748 | $28 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 11 | $300 | $27 |
2021: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $33,062 | $66 |
| Return visit (30+ min) | 145 | $19,961 | $85 |
| Long return visit (40+ min) | 91 | $14,603 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $14,510 | $95 |
| Return visit (30+ min) | 55 | $8,577 | $119 |
| Long return visit (40+ min) | 33 | $6,653 | $166 |
| New patient visit (60+ min) | 37 | $6,184 | $167 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 55 | $3,556 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,849 | $119 |
| Telehealth originating site facility fee | 88 | $2,597 | $21 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $2,384 | $77 |
| Extended patient service without direct patient contact, first hour | 17 | $2,179 | $104 |
| New patient visit (45+ min) | 18 | $2,094 | $116 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 25 | $1,228 | $30 |
2020: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 89 | $33,418 | $67 |
| Return visit (30+ min) | 103 | $9,090 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $8,052 | $97 |
| Return visit (30+ min) | 77 | $7,150 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $7,012 | $180 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 44 | $5,629 | $128 |
| Long return visit (40+ min) | 32 | $4,052 | $110 |
| Long return visit (40+ min) | 33 | $2,675 | $79 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $2,507 | $72 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 33 | $1,745 | $29 |
| New patient visit (45+ min) | 17 | $1,558 | $92 |
| Extended patient service without direct patient contact, first hour | 14 | $1,413 | $94 |
| Telehealth originating site facility fee | 53 | $1,263 | $21 |
2019: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $34,325 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $13,398 | $184 |
| Return visit (30+ min) | 122 | $13,269 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $9,716 | $94 |
| Long return visit (40+ min) | 71 | $8,659 | $94 |
| Return visit (30+ min) | 57 | $5,850 | $66 |
| Long return visit (40+ min) | 31 | $4,089 | $97 |
| New patient visit (60+ min) | 23 | $3,356 | $146 |
| New patient visit (60+ min) | 20 | $3,180 | $159 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 33 | $1,883 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,609 | $124 |
| New patient visit (45+ min) | 14 | $1,283 | $92 |
| Extended patient service without direct patient contact, first hour | 11 | $1,074 | $98 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $710 | $36 |
2018: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 108 | $44,059 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $15,645 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $10,579 | $94 |
| Long return visit (40+ min) | 67 | $8,283 | $93 |
| Return visit (30+ min) | 68 | $6,764 | $66 |
| Long return visit (40+ min) | 44 | $5,923 | $93 |
| New patient visit (60+ min) | 35 | $5,161 | $147 |
| Return visit (30+ min) | 44 | $3,616 | $62 |
| New patient visit (60+ min) | 15 | $1,859 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,589 | $122 |
| New patient visit (45+ min) | 11 | $1,022 | $93 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $839 | $35 |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 90 | $34,787 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $12,509 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $10,283 | $93 |
| Long return visit (40+ min) | 52 | $6,614 | $92 |
| Long return visit (40+ min) | 49 | $6,372 | $87 |
| Return visit (30+ min) | 65 | $5,972 | $66 |
| Return visit (30+ min) | 32 | $3,683 | $66 |
| New patient visit (60+ min) | 26 | $3,606 | $139 |
| New patient visit (60+ min) | 23 | $3,166 | $138 |
| New patient visit (45+ min) | 14 | $1,283 | $92 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $734 | $35 |
2016: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $21,085 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $10,635 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $9,533 | $91 |
| Long return visit (40+ min) | 59 | $8,677 | $94 |
| Long return visit (40+ min) | 41 | $6,446 | $92 |
| Return visit (30+ min) | 41 | $3,712 | $59 |
| Return visit (30+ min) | 21 | $2,553 | $65 |
| New patient visit (60+ min) | 12 | $1,797 | $150 |
| New patient visit (45+ min) | 17 | $1,770 | $104 |
| New patient visit (60+ min) | 13 | $1,688 | $130 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,081 | $35 |
2015: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 89 | $22,062 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $9,680 | $93 |
| Long return visit (40+ min) | 50 | $6,917 | $97 |
| Return visit (30+ min) | 63 | $6,900 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,437 | $181 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $3,271 | $35 |
| New patient visit (60+ min) | 23 | $3,163 | $138 |
| New patient visit (45+ min) | 27 | $2,787 | $103 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,611 | $119 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,523 | $80 |
| Short return visit (20+ min) | 16 | $728 | $36 |
2014: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $5,060 | $64 |
| Return visit (30+ min) | 41 | $3,356 | $70 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $3,192 | $35 |
| New patient visit (60+ min) | 20 | $2,876 | $144 |
| Long return visit (40+ min) | 20 | $2,664 | $99 |
Medicaid work
$81,010 in 2024
Medicaid paid $81,010 for 1,333 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 210 | $26,871 |
| Return visit (30+ min) | 320 | $26,148 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 754 | $25,952 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 49 | $2,039 |
| 2024 | 1,333 | 4 | 38 | $81,010 |
| 2023 | 1,586 | 6 | 47 | $71,254 |
| 2022 | 870 | 5 | 40 | $37,643 |
| 2021 | 808 | 4 | 42 | $31,633 |
| 2020 | 321 | 3 | 33 | $12,887 |
| 2019 | 225 | 2 | 28 | $9,199 |
| 2018 | 319 | 3 | 21 | $13,487 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 809 | $26,751 |
| Long return visit (40+ min) | 326 | $23,581 |
| Return visit (30+ min) | 376 | $17,353 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 48 | $2,713 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 12 | $512 |
| Telehealth originating site facility fee | 15 | $344 |
2022
| Long return visit (40+ min) | 218 | $15,422 |
| Return visit (30+ min) | 270 | $13,096 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 283 | $5,642 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 40 | $1,948 |
| Telehealth originating site facility fee | 59 | $1,536 |
2021
| Return visit (30+ min) | 358 | $15,499 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 322 | $8,507 |
| Long return visit (40+ min) | 102 | $6,999 |
| Telehealth originating site facility fee | 26 | $629 |
2020
| Return visit (30+ min) | 215 | $9,843 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 92 | $1,976 |
| Long return visit (40+ min) | 14 | $1,068 |
2019
| Return visit (30+ min) | 211 | $8,389 |
| Long return visit (40+ min) | 14 | $810 |
2018
| Return visit (30+ min) | 162 | $7,079 |
| Long return visit (40+ min) | 56 | $3,563 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 101 | $2,845 |
Drugs they prescribed that Part D paid
$2,077,907
Pharmacies billed $2,077,907 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,278) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
795 generic and 1,292 brand-name prescriptions · $2,077,907 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Korlym | 12 | $907,645 | $75,637 |
| Trulicity | 179 | $229,812 | $1,284 |
| Mounjaro | 175 | $228,940 | $1,308 |
| Ozempic | 117 | $185,477 | $1,585 |
| Jardiance | 116 | $141,719 | $1,222 |
See all 42 drugs
| Korlym | 12 | $907,645 | $75,637 |
| Trulicity | 179 | $229,812 | $1,284 |
| Mounjaro | 175 | $228,940 | $1,308 |
| Ozempic | 117 | $185,477 | $1,585 |
| Jardiance | 116 | $141,719 | $1,222 |
| Rybelsus | 28 | $51,220 | $1,829 |
| Januvia | 33 | $26,185 | $793 |
| Fiasp Flextouch | 17 | $20,129 | $1,184 |
| Tresiba Flextouch U-200 | 21 | $17,596 | $838 |
| Humalog Kwikpen U-200 | 16 | $17,497 | $1,094 |
| Basaglar Kwikpen U-100 | 29 | $17,033 | $587 |
| Humalog Kwikpen U-100 | 53 | $13,848 | $261 |
| Tresiba Flextouch U-100 | 17 | $11,944 | $703 |
| Insulin Aspart Flexpen | 26 | $10,100 | $388 |
| Nano 2nd Gen Pen Needle | 54 | $8,539 | $158 |
| Novolog Mix 70-30 Flexpen | 30 | $6,343 | $211 |
| Novolog Flexpen | 32 | $6,336 | $198 |
| Lantus Solostar | 46 | $5,641 | $123 |
| Testosterone | 11 | $5,240 | $476 |
| Tirosint | 15 | $4,952 | $330 |
| Synthroid | 50 | $4,834 | $97 |
| Ultra-Fine Mini Pen Needle | 43 | $4,255 | $99 |
| Insulin Lispro Kwikpen U-100 | 19 | $3,871 | $204 |
| Thyquidity | 11 | $2,948 | $268 |
| Hydrocortisone | 39 | $2,946 | $76 |
| Levothyroxine | 277 | $2,805 | $10 |
| Ultra-Fine Nano Pen Needle | 17 | $2,353 | $138 |
| Ultra-Fine Short Pen Needle | 13 | $2,150 | $165 |
| Comfort Ez Pen Needle | 24 | $2,054 | $86 |
| Novolin 70-30 Flexpen | 11 | $1,777 | $162 |
| Insulin Lispro Protamine Mix | 11 | $1,692 | $154 |
| Droplet Pen Needle | 11 | $1,569 | $143 |
| Insulin Glargine-Yfgn | 13 | $1,319 | $101 |
| Glipizide | 117 | $1,279 | $11 |
| Acarbose | 16 | $1,092 | $68 |
| Metformin | 150 | $1,046 | $7 |
| Metformin Hcl Er | 78 | $1,043 | $13 |
| Glyburide | 21 | $1,040 | $50 |
| Methimazole | 32 | $524 | $16 |
| Alendronate | 30 | $290 | $10 |
| Prednisone | 11 | $247 | $22 |
| Atorvastatin | 28 | $187 | $7 |
Year by year
| 2024 | 2,278 | 235 | 0% (0) | 57% | $2,077,907 |
| 2023 | 2,087 | 216 | 0% (0) | 52% | $1,333,901 |
| 2022 | 2,201 | 221 | 0% (0) | 52% | $1,338,564 |
| 2021 | 2,376 | 249 | 0% (0) | 54% | $1,324,197 |
| 2020 | 2,057 | 249 | 0% (0) | 53% | $932,196 |
| 2019 | 1,938 | 257 | 0% (0) | 50% | $831,150 |
| 2018 | 1,785 | 217 | 0% (0) | 50% | $615,541 |
| 2017 | 1,467 | 181 | 0% (0) | 51% | $460,785 |
| 2016 | 1,107 | 140 | 0% (0) | 51% | $309,066 |
| 2015 | 859 | 108 | 0% (0) | 50% | $214,900 |
| 2014 | 336 | 86 | 0% (0) | 46% | $59,635 |
| 2013 | 272 | 70 | 0% (0) | 48% | $67,405 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Trulicity | 180 | $351,826 | $1,955 |
| Jardiance | 90 | $138,044 | $1,534 |
| Novolog Flexpen | 86 | $107,782 | $1,253 |
| Mounjaro | 66 | $92,926 | $1,408 |
| Ozempic | 46 | $68,815 | $1,496 |
| Januvia | 49 | $41,569 | $848 |
| Humalog Kwikpen U-100 | 46 | $39,786 | $865 |
| Lantus Solostar | 48 | $33,836 | $705 |
| Humalog Kwikpen U-200 | 15 | $29,065 | $1,938 |
| Rybelsus | 15 | $26,653 | $1,777 |
| Humulin R U-500 Kwikpen | 22 | $24,293 | $1,104 |
| Basaglar Kwikpen U-100 | 36 | $23,142 | $643 |
| Farxiga | 13 | $22,914 | $1,763 |
| Novolog Mix 70-30 Flexpen | 23 | $22,566 | $981 |
| Insulin Aspart Flexpen | 33 | $20,466 | $620 |
| Tresiba Flextouch U-200 | 21 | $17,701 | $843 |
| Tresiba Flextouch U-100 | 18 | $8,982 | $499 |
| Novolin 70-30 Flexpen | 12 | $6,997 | $583 |
| Nano 2nd Gen Pen Needle | 40 | $6,934 | $173 |
| Levothyroxine | 253 | $4,311 | $17 |
| Ultra-Fine Short Pen Needle | 28 | $3,201 | $114 |
| Ultra-Fine Mini Pen Needle | 18 | $3,126 | $174 |
| Synthroid | 27 | $2,960 | $110 |
| Ketoconazole | 11 | $2,323 | $211 |
| Glipizide | 129 | $2,284 | $18 |
| Ultra-Fine Nano Pen Needle | 14 | $2,113 | $151 |
| Sure Comfort Pen Needle | 30 | $2,020 | $67 |
| Insulin Glargine-Yfgn | 11 | $2,013 | $183 |
| Comfort Ez Pen Needle | 19 | $1,968 | $104 |
| Metformin | 178 | $1,885 | $11 |
| Hydrocortisone | 25 | $1,817 | $73 |
| Droplet Pen Needle | 14 | $1,781 | $127 |
| Acarbose | 17 | $1,754 | $103 |
| Metformin Hcl Er | 85 | $1,510 | $18 |
| Glyburide | 16 | $1,471 | $92 |
| Alendronate | 38 | $494 | $13 |
| Methimazole | 15 | $412 | $27 |
| Atorvastatin | 24 | $349 | $15 |
2022: 34 drugs
| Trulicity | 203 | $370,551 | $1,825 |
| Novolog Flexpen | 117 | $134,289 | $1,148 |
| Jardiance | 81 | $109,741 | $1,355 |
| Humalog Kwikpen U-100 | 58 | $72,552 | $1,251 |
| Lantus Solostar | 114 | $67,603 | $593 |
| Januvia | 63 | $61,507 | $976 |
| Ozempic | 43 | $55,754 | $1,297 |
| Novolog Mix 70-30 Flexpen | 37 | $44,740 | $1,209 |
| Forteo | 11 | $41,829 | $3,803 |
| Rybelsus | 12 | $30,119 | $2,510 |
| Toujeo Solostar | 15 | $29,451 | $1,963 |
| Basaglar Kwikpen U-100 | 54 | $28,723 | $532 |
| Humulin R U-500 Kwikpen | 19 | $18,803 | $990 |
| Tresiba Flextouch U-100 | 27 | $15,028 | $557 |
| Victoza 3-Pak | 14 | $13,997 | $1,000 |
| Tresiba Flextouch U-200 | 11 | $10,677 | $971 |
| Comfort Ez Pen Needle | 61 | $6,401 | $105 |
| Nano 2nd Gen Pen Needle | 38 | $5,239 | $138 |
| Ultra-Fine Short Pen Needle | 27 | $4,925 | $182 |
| Levothyroxine | 231 | $4,902 | $21 |
| Synthroid | 36 | $3,710 | $103 |
| Ultra-Fine Mini Pen Needle | 15 | $2,352 | $157 |
| Glipizide | 165 | $2,226 | $13 |
| Hydrocortisone | 22 | $1,937 | $88 |
| Metformin | 190 | $1,861 | $10 |
| Droplet Pen Needle | 17 | $1,858 | $109 |
| Metformin Hcl Er | 79 | $1,821 | $23 |
| Acarbose | 17 | $1,676 | $99 |
| Glyburide | 15 | $1,394 | $93 |
| Atorvastatin | 23 | $533 | $23 |
| Alendronate | 56 | $526 | $9 |
| Pentips | 14 | $512 | $37 |
| Methimazole | 13 | $236 | $18 |
| Lisinopril | 13 | $148 | $11 |
2021: 36 drugs
| Trulicity | 242 | $400,459 | $1,655 |
| Novolog Flexpen | 143 | $148,435 | $1,038 |
| Lantus Solostar | 143 | $97,506 | $682 |
| Jardiance | 71 | $92,315 | $1,300 |
| Humalog Kwikpen U-100 | 52 | $49,581 | $953 |
| Januvia | 56 | $48,487 | $866 |
| Ozempic | 35 | $46,553 | $1,330 |
| Victoza 3-Pak | 31 | $34,548 | $1,114 |
| Novolog Mix 70-30 Flexpen | 31 | $28,806 | $929 |
| Basaglar Kwikpen U-100 | 46 | $25,576 | $556 |
| Humalog Kwikpen U-200 | 11 | $23,259 | $2,114 |
| Tresiba Flextouch U-100 | 41 | $21,994 | $536 |
| Humulin R U-500 | 13 | $21,841 | $1,680 |
| Toujeo Solostar | 16 | $20,896 | $1,306 |
| Tradjenta | 13 | $19,175 | $1,475 |
| Humulin R U-500 Kwikpen | 13 | $14,293 | $1,099 |
| Novolog | 11 | $14,077 | $1,280 |
| Humalog Mix 75-25 Kwikpen | 14 | $11,536 | $824 |
| Insulin Lispro Kwikpen U-100 | 24 | $9,460 | $394 |
| Comfort Ez Pen Needle | 57 | $7,066 | $124 |
| Ultra-Fine Short Pen Needle | 44 | $5,696 | $129 |
| Levothyroxine | 233 | $5,332 | $23 |
| Nano 2nd Gen Pen Needle | 45 | $4,372 | $97 |
| Synthroid | 37 | $3,721 | $101 |
| Hydrocortisone | 30 | $2,759 | $92 |
| Glipizide | 192 | $2,690 | $14 |
| Ultra-Fine Nano Pen Needle | 16 | $2,531 | $158 |
| Metformin | 203 | $2,024 | $10 |
| Acarbose | 18 | $2,021 | $112 |
| Metformin Hcl Er | 69 | $1,675 | $24 |
| Glyburide | 14 | $646 | $46 |
| Atorvastatin | 26 | $626 | $24 |
| Liothyronine | 12 | $611 | $51 |
| Alendronate | 51 | $560 | $11 |
| Methimazole | 17 | $335 | $20 |
| Lisinopril | 24 | $312 | $13 |
2020: 34 drugs
| Trulicity | 143 | $206,508 | $1,444 |
| Novolog Flexpen | 150 | $144,324 | $962 |
| Victoza 3-Pak | 81 | $88,942 | $1,098 |
| Lantus Solostar | 108 | $73,958 | $685 |
| Januvia | 55 | $64,130 | $1,166 |
| Jardiance | 36 | $37,127 | $1,031 |
| Basaglar Kwikpen U-100 | 37 | $23,311 | $630 |
| Humalog Mix 75-25 Kwikpen | 26 | $21,854 | $841 |
| Toujeo Solostar | 20 | $21,164 | $1,058 |
| Humalog Kwikpen U-100 | 19 | $20,249 | $1,066 |
| Novolog Mix 70-30 Flexpen | 23 | $19,077 | $829 |
| Cinacalcet | 15 | $18,360 | $1,224 |
| Tresiba Flextouch U-100 | 28 | $15,403 | $550 |
| Insulin Lispro Kwikpen U-100 | 13 | $14,346 | $1,104 |
| Tresiba Flextouch U-200 | 16 | $12,521 | $783 |
| Humulin N Kwikpen | 11 | $9,920 | $902 |
| Ultra-Fine Nano Pen Needle | 47 | $6,032 | $128 |
| Levothyroxine | 211 | $5,909 | $28 |
| Ultra-Fine Short Pen Needle | 41 | $5,510 | $134 |
| Comfort Ez Pen Needle | 45 | $4,269 | $95 |
| Synthroid | 30 | $3,126 | $104 |
| Glipizide | 166 | $2,706 | $16 |
| Ulticare Pen Needle | 13 | $2,389 | $184 |
| Acarbose | 23 | $2,099 | $91 |
| Ultra-Fine Mini Pen Needle | 15 | $1,982 | $132 |
| Hydrocortisone | 37 | $1,957 | $53 |
| Metformin | 181 | $1,813 | $10 |
| Ultracare Pen Needle | 12 | $1,453 | $121 |
| Nano 2nd Gen Pen Needle | 13 | $1,316 | $101 |
| Metformin Hcl Er | 53 | $1,255 | $24 |
| Atorvastatin | 25 | $512 | $20 |
| Methimazole | 22 | $488 | $22 |
| Alendronate | 39 | $327 | $8 |
| Lisinopril | 27 | $278 | $10 |
2019: 37 drugs
| Trulicity | 100 | $126,270 | $1,263 |
| Novolog Flexpen | 114 | $102,834 | $902 |
| Victoza 3-Pak | 83 | $85,409 | $1,029 |
| Lantus Solostar | 99 | $57,088 | $577 |
| Januvia | 55 | $54,164 | $985 |
| Novolog Mix 70-30 Flexpen | 41 | $41,987 | $1,024 |
| Jardiance | 40 | $37,226 | $931 |
| Cinacalcet | 21 | $25,814 | $1,229 |
| Humalog Kwikpen U-100 | 29 | $22,330 | $770 |
| Humalog Mix 75-25 Kwikpen | 29 | $20,301 | $700 |
| Tresiba Flextouch U-200 | 16 | $15,762 | $985 |
| Tresiba Flextouch U-100 | 26 | $15,287 | $588 |
| Toujeo Solostar | 19 | $15,206 | $800 |
| Basaglar Kwikpen U-100 | 37 | $15,091 | $408 |
| Novolog | 17 | $11,479 | $675 |
| Lantus | 17 | $8,973 | $528 |
| Levothyroxine | 225 | $6,441 | $29 |
| Glucagon Emergency Kit | 12 | $5,987 | $499 |
| Ultra-Fine Nano Pen Needle | 51 | $5,094 | $100 |
| Ultra-Fine Short Pen Needle | 42 | $5,057 | $120 |
| Synthroid | 22 | $2,349 | $107 |
| Acarbose | 28 | $2,039 | $73 |
| Hydrocortisone | 30 | $1,986 | $66 |
| Comfort Ez Pen Needle | 20 | $1,964 | $98 |
| Metformin | 165 | $1,795 | $11 |
| Glipizide | 162 | $1,722 | $11 |
| Ultra-Fine Mini Pen Needle | 17 | $1,303 | $77 |
| Metformin Hcl Er | 52 | $803 | $15 |
| Atorvastatin | 28 | $668 | $24 |
| Glyburide | 11 | $536 | $49 |
| Unifine Pentips | 17 | $527 | $31 |
| Methimazole | 17 | $261 | $15 |
| Glipizide Er | 12 | $232 | $19 |
| Glimepiride | 13 | $219 | $17 |
| Lisinopril | 18 | $155 | $9 |
| Alendronate | 17 | $154 | $9 |
| Amlodipine Besylate | 12 | $61 | $5 |
2018: 43 drugs
| Novolog Flexpen | 86 | $61,668 | $717 |
| Victoza 3-Pak | 51 | $54,249 | $1,064 |
| Januvia | 54 | $51,385 | $952 |
| Novolog Mix 70-30 Flexpen | 60 | $50,988 | $850 |
| Lantus Solostar | 96 | $46,808 | $488 |
| Humalog Kwikpen U-100 | 55 | $41,901 | $762 |
| Humulin R U-500 Kwikpen | 21 | $29,033 | $1,383 |
| Humalog Mix 75-25 Kwikpen | 37 | $22,754 | $615 |
| Toujeo Solostar | 18 | $20,809 | $1,156 |
| Tradjenta | 17 | $20,725 | $1,219 |
| Tresiba Flextouch U-100 | 36 | $20,531 | $570 |
| Jardiance | 14 | $19,437 | $1,388 |
| Bydureon | 14 | $17,440 | $1,246 |
| Sensipar | 17 | $14,691 | $864 |
| Trulicity | 17 | $13,983 | $823 |
| Tresiba Flextouch U-200 | 20 | $12,304 | $615 |
| Novolog | 16 | $11,437 | $715 |
| Humalog | 13 | $10,054 | $773 |
| Lantus | 13 | $6,759 | $520 |
| Basaglar Kwikpen U-100 | 18 | $6,059 | $337 |
| Humulin N Kwikpen | 12 | $5,599 | $467 |
| Levothyroxine | 192 | $5,439 | $28 |
| Levemir Flextouch | 11 | $5,282 | $480 |
| Ultra-Fine Nano Pen Needle | 52 | $5,280 | $102 |
| Ultra-Fine Short Pen Needle | 30 | $2,951 | $98 |
| Synthroid | 30 | $2,711 | $90 |
| Metformin | 158 | $1,620 | $10 |
| Hydrocortisone | 20 | $1,181 | $59 |
| Glipizide | 117 | $1,066 | $9 |
| Acarbose | 16 | $923 | $58 |
| Atorvastatin | 63 | $921 | $15 |
| Unifine Pentips | 22 | $888 | $40 |
| Ultra-Fine Mini Pen Needle | 14 | $833 | $59 |
| Glipizide Er | 24 | $467 | $19 |
| Metformin Hcl Er | 33 | $400 | $12 |
| Sure Comfort | 12 | $370 | $31 |
| Losartan | 17 | $291 | $17 |
| Glyburide | 11 | $266 | $24 |
| Methimazole | 20 | $221 | $11 |
| Amlodipine Besylate | 24 | $137 | $6 |
| Lisinopril | 22 | $123 | $6 |
| Glimepiride | 12 | $53 | $4 |
| Single Use Swab | 11 | $22 | $2 |
2017: 32 drugs
| Lantus Solostar | 118 | $53,188 | $451 |
| Novolog Flexpen | 68 | $44,779 | $659 |
| Victoza 3-Pak | 50 | $41,578 | $832 |
| Humalog Kwikpen U-100 | 48 | $37,395 | $779 |
| Januvia | 29 | $27,360 | $943 |
| Humalog Mix 75-25 Kwikpen | 51 | $26,404 | $518 |
| Novolog Mix 70-30 Flexpen | 23 | $24,602 | $1,070 |
| Tradjenta | 30 | $21,530 | $718 |
| Bydureon | 19 | $20,747 | $1,092 |
| Humulin R U-500 | 11 | $18,633 | $1,694 |
| Toujeo Solostar | 24 | $16,322 | $680 |
| Humulin R U-500 Kwikpen | 16 | $15,820 | $989 |
| Tresiba Flextouch U-200 | 18 | $14,581 | $810 |
| Novolog | 21 | $11,626 | $554 |
| Tresiba Flextouch U-100 | 19 | $9,988 | $526 |
| Lantus | 15 | $8,645 | $576 |
| Ultra-Fine Nano Pen Needle | 39 | $3,921 | $101 |
| Levothyroxine | 129 | $3,577 | $28 |
| Synthroid | 37 | $2,648 | $72 |
| Ultra-Fine Mini Pen Needle | 25 | $1,673 | $67 |
| Ultra-Fine Short Pen Needle | 23 | $1,618 | $70 |
| Hydrocortisone | 30 | $1,597 | $53 |
| Metformin Hcl Er | 34 | $1,273 | $37 |
| Metformin | 128 | $1,265 | $10 |
| Glipizide | 82 | $847 | $10 |
| Atorvastatin | 65 | $758 | $12 |
| Methimazole | 33 | $395 | $12 |
| Pen Needles | 15 | $359 | $24 |
| Glimepiride | 17 | $183 | $11 |
| Glipizide Xl | 15 | $115 | $8 |
| Lisinopril | 16 | $103 | $6 |
| Amlodipine Besylate | 13 | $98 | $8 |
2016: 24 drugs
| Lantus Solostar | 114 | $46,218 | $405 |
| Humulin R U-500 | 24 | $41,331 | $1,722 |
| Humalog Kwikpen U-100 | 64 | $37,658 | $588 |
| Tradjenta | 41 | $28,278 | $690 |
| Januvia | 27 | $23,798 | $881 |
| Novolog Flexpen | 25 | $17,397 | $696 |
| Lantus | 35 | $13,694 | $391 |
| Novolog Mix 70-30 Flexpen | 19 | $10,702 | $563 |
| Toujeo Solostar | 18 | $7,899 | $439 |
| Bd Ultra-Fine Pen Needle | 75 | $5,540 | $74 |
| Humalog | 19 | $5,536 | $291 |
| Novolog | 18 | $5,058 | $281 |
| Levemir Flextouch | 11 | $4,504 | $409 |
| Synthroid | 46 | $3,400 | $74 |
| Metformin Hcl Er | 20 | $2,741 | $137 |
| Levothyroxine | 72 | $2,085 | $29 |
| Metformin | 79 | $1,018 | $13 |
| Hydrocortisone | 24 | $998 | $42 |
| Atorvastatin | 53 | $808 | $15 |
| Glipizide | 68 | $794 | $12 |
| Insulin | 15 | $669 | $45 |
| Methimazole | 23 | $423 | $18 |
| Glipizide Xl | 12 | $186 | $15 |
| Lisinopril | 20 | $108 | $5 |
2015: 23 drugs
| Lantus Solostar | 69 | $32,259 | $468 |
| Novolog Flexpen | 54 | $30,434 | $564 |
| Tradjenta | 25 | $23,064 | $923 |
| Humulin R U-500 | 17 | $22,983 | $1,352 |
| Januvia | 15 | $13,736 | $916 |
| Humalog Kwikpen U-100 | 21 | $13,642 | $650 |
| Novolog Mix 70-30 Flexpen | 21 | $13,439 | $640 |
| Lantus | 21 | $9,644 | $459 |
| Novolog | 28 | $8,707 | $311 |
| Byetta | 11 | $7,518 | $683 |
| Levemir | 15 | $5,323 | $355 |
| Bd Ultra-Fine Pen Needle | 53 | $3,459 | $65 |
| Tirosint | 18 | $2,168 | $120 |
| Synthroid | 27 | $1,861 | $69 |
| Levothyroxine | 61 | $1,776 | $29 |
| Hydrocortisone | 30 | $1,514 | $50 |
| Metformin Hcl Er | 13 | $1,193 | $92 |
| Metformin | 73 | $878 | $12 |
| Atorvastatin | 36 | $578 | $16 |
| Liothyronine | 15 | $483 | $32 |
| Glipizide | 39 | $344 | $9 |
| Alendronate | 12 | $136 | $11 |
| Lisinopril | 15 | $83 | $6 |
2014: 8 drugs
| Lantus Solostar | 29 | $11,536 | $398 |
| Novolog | 21 | $5,441 | $259 |
| Bd Ultra-Fine Pen Needle | 19 | $886 | $47 |
| Hydrocortisone | 19 | $786 | $41 |
| Levothyroxine | 37 | $719 | $19 |
| Alendronate | 20 | $217 | $11 |
| Glipizide | 22 | $192 | $9 |
| Metformin | 12 | $114 | $9 |
2013: 7 drugs
| Forteo | 21 | $22,688 | $1,080 |
| Lantus | 15 | $4,802 | $320 |
| Novolog | 14 | $3,295 | $235 |
| Insulin | 15 | $757 | $50 |
| Levothyroxine | 23 | $416 | $18 |
| Alendronate | 27 | $345 | $13 |
| Insulin | 11 | $255 | $23 |
Money from drug and device companies
$12,817 in 2025
| 2025 | 4 | 17 | $8,115 | $12,817 |
| 2024 | 5 | 5 | $3,613 | $3,951 |
| 2023 | 1 | 1 | $3,400 | $3,400 |
| 2022 | 3 | 4 | $1,488 | $1,676 |
| 2020 | 2 | 2 | $688 | $810 |
| 2019 | 6 | 12 | None | $702 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Vertex Pharmaceuticals | None | $7,404 | 14 payments
|
| Novo Nordisk | None | $5,115 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $153 | 1 payment
|
| Sequel Med Tech | Twiist | $145 | 1 payment
|
See all 17 published payments
| Vertex Pharmaceuticals | Travel · 2025-10-29 | None | $85 |
| Vertex Pharmaceuticals | Meals · 2025-10-29 | None | $18 |
| Vertex Pharmaceuticals | Meals · 2025-10-29 | None | $6 |
| Vertex Pharmaceuticals | Meals · 2025-10-29 | None | $29 |
| Vertex Pharmaceuticals | Travel · 2025-10-29 | None | $42 |
| Vertex Pharmaceuticals | Travel · 2025-10-29 | None | $2,695 |
| Vertex Pharmaceuticals | Meals · 2025-10-29 | None | $31 |
| Vertex Pharmaceuticals | Travel · 2025-10-29 | None | $74 |
| Vertex Pharmaceuticals | Consulting · 2025-10-29 | None | $3,000 |
| Dexcom | Meals · 2025-10-23 | Dexcom G6 Transmitter | $153 |
| Vertex Pharmaceuticals | Travel · 2025-10-10 | None | $195 |
| Vertex Pharmaceuticals | Meals · 2025-10-10 | None | $23 |
| Vertex Pharmaceuticals | Travel · 2025-10-10 | None | $822 |
| Vertex Pharmaceuticals | Meals · 2025-10-10 | None | $37 |
| Vertex Pharmaceuticals | Travel · 2025-10-09 | None | $348 |
| Sequel Med Tech | Meals · 2025-09-15 | Twiist | $145 |
| Novo Nordisk | Consulting · 2025-01-01 | None | $5,115 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $3,951
| Novo Nordisk | None | $3,613 | 1 payment
|
| Beta Bionics | Ilet Bionic Pancreas | $164 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $121 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $33 | 1 payment
|
| EMD Serono | Mavenclad | $20 | 1 payment
|
2023: $3,400
| Novo Nordisk | None | $3,400 | 1 payment
|
2022: $1,676
| Novo Nordisk | None | $1,488 | 1 payment
|
| Lilly USA | Mounjaro | $127 | 2 payments
|
| Eiger Biopharmaceuticals | Zokinvy | $61 | 1 payment
|
2020: $810
| Bayer HealthCare Pharmaceuticals | Non-Covered | $688 | 1 payment
|
| Amgen | Repatha | $122 | 1 payment
|
2019: $702
| Novo Nordisk | Ozempic | $237 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $171 | 2 payments
|
| Tandem Diabetes Care | T-Slim Insulin Pump | $140 | 2 payments
|
| Mannkind | Afrezza | $127 | 2 payments
|
| Medtronic MiniMed | Minimed 670g System | $15 | 1 payment
|
| Insulet | Omnipod | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1770899395
- Licence
- CA A113366California A113366: Current · expires 2027-10-31
- Trained
- Boston University School of Medicine, 2009 · 17 years ago
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-08-19
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.